The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads.

Although the improvement over SG alone did not reach statistical significance ( p = 0.34), further analysis of individual tumor volume changes indicated that by end of study (day 46), all tumors in the combination treatment group remained small (<500 mm 3 ) or exhibited regression, whereas 63% (5/8) or 50% (4/8) of tumors in the azenosertib or SG monotherapy groups, respectively, had more than doubled in size (>500 mm 3 ; Figure 2 D).

also in 111,027 other papers